Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety/Tolerability of IV Rhu-pGSN as a Pre- or Post-Exposure Intervention to Mitigate Proinflammatory Responses to Decompression After High Pressure in a Hyperbaric Chamber
Sponsor: BioAegis Therapeutics Inc.
This PHASE2 trial investigates Decompression Sickness and is currently ongoing. BioAegis Therapeutics Inc. leads this study, which shows 8 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
▶ Show 3 earlier versions
-
Sep 2024 — Apr 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioAegis Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .